about
Role of chemotherapy in the management of vulvar carcinoma.Endometrial marginal zone B-cell MALT-type lymphoma: case report and literature review.The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis.Cervical cancer: are there potential new targets? An update on preclinical and clinical results.Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis.Management of Endometriomas.Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene.Vaginectomy: a minimally invasive treatment for cervical cancer vaginal recurrence.A medical device containing purified bovine colostrum (Monurelle Biogel) in the treatment of vulvovaginal atrophy in postmenopausal women: Retrospective analysis of urinary symptoms, sexual function, and quality of life.Orally Administered Combination of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin in the Prevention of Postcoital Recurrent Urinary Tract Infections: Analysis of 98 Women in Reproductive Age After 6 Months of Treatment.Fertility management for malignant ovarian germ cell tumors patients.Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?Current management of ovarian endometriomas.Erratum: Management of Endometriomas.Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms.Usefulness of Ospemifene in the treatment of urgency in menopausal patients affected by mixed urinary incontinence underwent mid-urethral slings surgeryManagement of endometriosis from diagnosis to treatment. Roadmap for the futureAntimüllerian hormone is reduced in the presence of ovarian endometriomas: a systematic review and meta-analysisTherapeutic vaccines and immune checkpoints inhibition options for gynecological cancersA prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancerImmunotherapy in endometrial cancer: new scenarios on the horizonContinuous versus cyclic oral contraceptives for endometriosis: any conclusive evidence?Long-term experience of vaginal vault prolapse prevention at hysterectomy time by modified McCall culdoplasty or Shull suspension: Clinical, sexual and quality of life assessment after surgical interventionAlpha lipoic acid in obstetrics and gynecologyPelvic Inflammatory Disease: Possible Catches and Correct Management in Young WomenOvarian Reserve Reduction With Surgery Is Not Correlated With the Amount of Ovarian Tissue Inadvertently Excised at Laparoscopic Surgery for EndometriomasMedical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain
P50
Q37878049-05913C02-CC56-4DC4-A7C3-61846E41F74FQ38117986-8CA840F5-22AE-4E08-98A7-B1F24C74C486Q38236206-7D553C38-D1AA-4B65-8574-A7EEC3365B92Q38258603-68670CF4-1909-4AC6-87F4-60FAD5C16F10Q38585908-AD9E9A7C-7528-4F95-B1E9-EA173C6AA7CCQ39162941-F6603622-9F85-4410-85D9-0502A8EBFB8BQ40074836-F60E2DCF-862F-4760-8D81-3BEAB2E4FE32Q43800896-8A8930F7-7B3A-4E6F-BE50-74A2A322770CQ47422709-138DCCB2-E6AB-4FAC-A968-8FA65F51EAD5Q47547425-8B1E1326-E3AE-412C-B4D9-04EA303A563DQ49341364-B0DBC0B7-8DD5-4A05-9DCA-91863778EBE2Q49797291-B70E1194-26BA-4207-A6BC-7CD4B14A2B9BQ50071438-30B3E3DF-67C3-4609-9E2E-32521D89B217Q50075024-C795E7D5-2CD4-4BEF-8140-9ABADCF33386Q53496298-D55905C4-853B-40E1-9427-B5BDCE2A96A0Q57457405-8EBEDAC4-A7BC-4C82-BBAE-70C722CF4B6BQ57476459-D3986DCF-5735-4B6D-A8DE-4AD27EFFF75BQ57486285-0A085D03-97D2-4818-BF46-ED51F655A188Q59357891-16F7171E-846A-4150-81CB-148A01BD7A3CQ63412833-E5D34957-D038-4BF8-8855-CBAA77ABB099Q64270860-554434CB-E0F3-49A7-BFEE-FFA4DAB3135FQ85290790-3B646567-938B-4FC9-A593-B9973ABAA960Q88004152-12CC1C12-D0D8-481B-884F-4C14BED0291CQ88566528-5809E791-0327-4E61-8573-047779C21B6FQ90968766-AE176B9B-2AD6-45EA-934C-9620D980C19EQ91588741-37FA27ED-3E32-4653-AFAC-9E3529C524F8Q91873351-E011E4B0-60A0-4C10-BA43-F156DD62FD62
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
C Di Tucci
@en
C Di Tucci
@nl
type
label
C Di Tucci
@en
C Di Tucci
@nl
prefLabel
C Di Tucci
@en
C Di Tucci
@nl
P31
P496
0000-0002-1292-9672